Free Trial

Biomerica (BMRA) Competitors

Biomerica logo
$2.88 +0.02 (+0.56%)
As of 01:54 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BMRA vs. QTTB, DARE, PMN, KZR, CVKD, ENLV, XCUR, LPTX, MTVA, and ALLR

Should you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Q32 Bio (QTTB), Dare Bioscience (DARE), Promis Neurosciences (PMN), Kezar Life Sciences (KZR), Cadrenal Therapeutics (CVKD), Enlivex Therapeutics (ENLV), Exicure (XCUR), Leap Therapeutics (LPTX), MetaVia (MTVA), and Allarity Therapeutics (ALLR). These companies are all part of the "pharmaceutical products" industry.

Biomerica vs. Its Competitors

Q32 Bio (NASDAQ:QTTB) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

In the previous week, Biomerica had 5 more articles in the media than Q32 Bio. MarketBeat recorded 8 mentions for Biomerica and 3 mentions for Q32 Bio. Biomerica's average media sentiment score of 0.84 beat Q32 Bio's score of 0.63 indicating that Biomerica is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Q32 Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Biomerica
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Q32 Bio has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500.

Q32 Bio has a net margin of 0.00% compared to Biomerica's net margin of -74.84%. Biomerica's return on equity of -74.32% beat Q32 Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Q32 BioN/A -2,709.70% -61.16%
Biomerica -74.84%-74.32%-53.24%

Biomerica has higher revenue and earnings than Q32 Bio. Biomerica is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Q32 Bio$1.16M37.18-$47.73M-$4.30-0.82
Biomerica$5.31M1.55-$4.97M-$2.32-1.24

31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 40.0% of Q32 Bio shares are owned by company insiders. Comparatively, 15.0% of Biomerica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Q32 Bio currently has a consensus price target of $12.17, indicating a potential upside of 244.18%. Given Q32 Bio's stronger consensus rating and higher probable upside, analysts plainly believe Q32 Bio is more favorable than Biomerica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Q32 Bio
1 Sell rating(s)
6 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.11
Biomerica
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Q32 Bio and Biomerica tied by winning 8 of the 16 factors compared between the two stocks.

Get Biomerica News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMRA vs. The Competition

MetricBiomericaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$8.27M$3.02B$6.15B$10.48B
Dividend YieldN/A57.77%5.73%4.78%
P/E Ratio-1.2422.9884.9827.27
Price / Sales1.55625.64574.66178.17
Price / CashN/A172.6337.3961.86
Price / Book1.795.4612.456.71
Net Income-$4.97M$33.06M$3.32B$276.79M
7 Day Performance-2.51%-0.96%0.28%-0.77%
1 Month Performance-4.13%13.17%10.12%6.38%
1 Year Performance5.67%-2.14%72.36%37.91%

Biomerica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMRA
Biomerica
0.4267 of 5 stars
$2.88
+0.6%
N/A+11.3%$8.27M$5.31M-1.2460News Coverage
Upcoming Earnings
Analyst Forecast
Gap Down
High Trading Volume
QTTB
Q32 Bio
2.9704 of 5 stars
$2.52
+16.1%
$12.17
+382.8%
-92.5%$30.74M$1.16M-0.5939News Coverage
Analyst Forecast
High Trading Volume
DARE
Dare Bioscience
1.9794 of 5 stars
$2.24
-0.4%
$10.00
+346.4%
-41.6%$30.20M$10K-1.0530Positive News
PMN
Promis Neurosciences
3.3261 of 5 stars
$0.54
-1.4%
$4.33
+701.0%
-54.1%$29.11MN/A-2.585
KZR
Kezar Life Sciences
3.7533 of 5 stars
$3.86
-1.8%
$9.00
+133.2%
-50.6%$28.27MN/A-0.4060High Trading Volume
CVKD
Cadrenal Therapeutics
2.3757 of 5 stars
$13.62
+0.7%
$32.00
+134.9%
-3.0%$27.92MN/A-1.534News Coverage
ENLV
Enlivex Therapeutics
2.7231 of 5 stars
$1.13
-1.3%
$10.00
+785.0%
-25.2%$27.45MN/A-1.9570
XCUR
Exicure
1.741 of 5 stars
$4.31
+0.9%
N/A+126.2%$27.24M$500K-1.1150Gap Up
LPTX
Leap Therapeutics
2.4541 of 5 stars
$0.63
-18.0%
$3.38
+438.8%
-72.8%$25.96MN/A-0.4040Gap Down
High Trading Volume
MTVA
MetaVia
2.8244 of 5 stars
$1.06
-1.9%
$7.50
+607.5%
N/A$25.65MN/A0.008
ALLR
Allarity Therapeutics
2.7556 of 5 stars
$1.75
+6.1%
$9.25
+428.6%
-9.6%$25.41MN/A0.0010

Related Companies and Tools


This page (NASDAQ:BMRA) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners